Myocardial Infarction pipeline therapeutics constitutes close to 118 molecules. Out of which approximately 93 molecules are developed by Companies and remaining by the Universities/Institutes. latest report Myocardial Infarction – Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Myocardial Infarction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Request sample at https://marketreportscenter.com/request-sample/438509
Myocardial Infarction Myocardial infarction is the irreversible necrosis of heart muscle secondary to prolonged ischemia. Symptoms include pain, fullness, and/or squeezing sensation of the chest, jaw pain, toothache, headache, shortness of breath, nausea, vomiting, and/or general epigastric discomfort, sweating, heartburn and/or indigestion, arm pain, upper back pain and general malaise (vague feeling of illness). The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 8, 18, 8, 1, 46, 7 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 16 and 7 molecules, respectively.
Check Discount at https://marketreportscenter.com/request-discount/438509
Furthermore, this report also reviews of key players involved in therapeutic development for Myocardial Infarction and features dormant and discontinued projects. Driven by data built using data and information sourced from Our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Know more details of report, Table of content, list of figures or purchase report at https://marketreportscenter.com/reports/438509/myocardial-infarction-pipeline-review-h2-2016
You can also reach me if you have any questions or need any assistance
Market Reports Center